October 25, 2012

A New Jersey judge has refused to halt multidistrict antitrust litigation challenging patent infringement settlements Pfizer Inc. reached over its cholesterol treatment Lipitor, ruling that waiting for the U.S. Supreme Court to take and decide similar suits over pay-for-delay deals would stall the case too long.

U.S. District Judge Peter G. Sheridan on Oct. 19 rejected a request from defendants Pfizer, Ranbaxy Inc. and others to stay the MDL until the Supreme Court decides whether it will review a Third Circuit case the plaintiffs have indicated they plan to rely on to make their case.

The plaintiffs' antitrust claims focus mainly on a settlement Pfizer reached with Ranbaxy to resolve the pharmaceutical giant's claims that Ranbaxy's bid to make a generic version of the blockbuster cholesterol drug would infringe its patent. They claim the two companies anti-competitively agreed to delay the entry of a generic challenger onto the market.

The full article can be read here